검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | or equivalent (Prednisone, Prednisone (or equivalent)) AstraZeneca·Chronic Lymphocytic Leukaemia ORR 45% |
|---|---|
Overview Program | Prednisone (or equivalent) |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukaemia |
Overview Indication | Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Comparative Efficacy and Safety of Telitacicept vs. Belimumab in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.. This study was designed to assess the comparative efficacy and safety of telitacicept and belimumab in adult patients diagnosed with systemic lupus erythematosus (SLE). We systematically searched MEDLINE, Embase, and Web of Science from database inception through M… |
Clinical Primary efficacy | ORR 45% |
Clinical ORR | 45% |
Clinical OS | 37 |
Clinical Result source | ClinicalTrials.gov NCT02133924 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | or equivalent (Prednisone, Prednisone (or equivalent)) AstraZeneca·Chronic Lymphocytic Leukaemia ORR 45% |
|---|---|
Overview Program | Prednisone (or equivalent) |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | Chronic Lymphocytic Leukaemia |
Overview Indication | Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
PK/PD Species | Rabbit |
PK/PD Animal (cat.) | Unknown |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Rabbit |
Toxicology Animal (cat.) | Unknown |
Toxicology Major finding | Comparative Efficacy and Safety of Telitacicept vs. Belimumab in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis.. This study was designed to assess the comparative efficacy and safety of telitacicept and belimumab in adult patients diagnosed with systemic lupus erythematosus (SLE). We systematically searched MEDLINE, Embase, and Web of Science from database inception through M… |
Clinical Primary efficacy | ORR 45% |
Clinical ORR | 45% |
Clinical OS | 37 |
Clinical Result source | ClinicalTrials.gov NCT02133924 |
Clinical Data Tier / Score | A · 54 |
Clinical Program phase | PHASE_2 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교